Skip to main content

Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs
Clinical Pathways GPS
04/21/2020
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
...
04/21/2020
Journal of Clinical Pathways